Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 16/20 | 0.46 |
| ▸ | NPY1R | P25929 | 10/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.46 |
| ▸ | NPY2R | P49146 | 6/20 | 0.46 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leupeptin SCHEMBL13933715 | 1.00 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| Leupeptin SCHEMBL4669504 | 1.00 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| Leupeptin SCHEMBL583830 | 1.00 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| Leupeptin SCHEMBL11596919 | 0.99 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL3308386 | 0.99 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL30643187 | 0.99 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL16316642 | 0.94 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| Leupeptin SCHEMBL25361 | 0.94 | NPY4R (0.51) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL11094153 | 0.92 | SMN1; SMN2 (0.42) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL24178182 | 0.92 | BACE1 (0.44) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11219670-B2 | Targeting CAPN9/CAPNS2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-01-11 | — | — | US | disclosed |
| US-8729024-B2 | Targeted delivery of pharmaceutical compounds | The Resesarch Foundation of State University of New York (US) | 2014-05-20 | — | — | US | disclosed |
| US-7968516-B2 | Taurine, cysteic acid residue and residue of a protease or calpain inhibitor; directly, indirectly bonded to each other;leucyl argininal residues in form of aldehyde; effective to inhibit calpains; acetal prodrug residues can be converted to the aldehyde form before, during, or after administration | ProTor Pharma Corporation (US) | 2011-06-28 | — | — | US | disclosed |
| US-20090227522-A1 | Targeted Delivery of Pharmaceutical Compounds | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2009-09-10 | — | — | US | disclosed |
| US-20080200399-A1 | Compounds for Treating Neurologic Diseases, Otologic Diseases, or Ophthalmologic Diseases and Methods of Use Thereof | PROTOR PHARMA CORP. | 2008-08-21 | — | — | US | disclosed |
| US-20080039531-A1 | Compositions, and kits comprising targeted aldehyde or acetal protease inhibitor compounds for treating muscle disorders | STRACHER ALFRED | 2008-02-14 | — | — | US | disclosed |
| EP-0144993-A2 | Promoting animal and plant growth with protease inhibitors | GENETIC DIAGNOSTIC CORPORATION (US) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11219670-B2 | Targeting CAPN9/CAPNS2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies | CAPN9, CAPNS1, CAPN2 | NPY4R 4547/4885NPY1R 4569/4885NPY5R 4758/4885 |
| US-20080200399-A1 | Compounds for Treating Neurologic Diseases, Otologic Diseases, or Ophthalmologic Diseases and Methods of Use Thereof | OTC, CLN6, OAT | NPY4R 2855/4885NPY1R 2641/4885NPY5R 2065/4885 |
| US-20080039531-A1 | Compositions, and kits comprising targeted aldehyde or acetal protease inhibitor compounds for treating muscle disorders | CPT1B, CAPNS1, CAPN1 | NPY4R 4822/4885NPY1R 4767/4885NPY5R 4691/4885 |
| US-20090227522-A1 | Targeted Delivery of Pharmaceutical Compounds | ABCG2, CLTB, APOB | NPY4R 1503/4885NPY1R 1153/4885NPY5R 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.